ERBB2 and breast cancer: The results showed that the higher the expression of OP-metagene, the shorter the RFS of breast cancer patients with luminal A (HR = 1.72, log rank p = 2.7e−10), luminal B (HR = 1.97, log rank p = 2.7e−12), basal-like (HR=1.52, log rank p = 0.0023), and HER2+ (HR = 1.45, log rank p = 0.06, in the edge of significance) (Figure 4I) subtypes, suggesting that OP-metagene may be a better biomarker for predicting disease progression in patients with breast cancer than IM-metagene.